Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals Inc (NYSE: AMRX) delivers essential medicines through its focus on affordable generics and specialty pharmaceuticals. This news hub provides investors and healthcare professionals with timely updates on regulatory developments, strategic partnerships, and operational milestones.
Our curated collection features official press releases and verified news coverage spanning key business segments. Track updates on generic drug approvals, manufacturing expansions, and AvKARE distribution network enhancements. Access filings related to FDA submissions, intellectual property developments, and corporate governance matters.
Discover comprehensive coverage of earnings announcements, research collaborations, and therapeutic area advancements. The resource serves as an objective reference for monitoring AMRX's role in improving medication accessibility while maintaining quality standards across global markets.
Bookmark this page for streamlined access to Amneal's latest developments in generic pharmaceuticals and complex drug formulations. Regularly updated content supports informed analysis of this NYSE-listed company's market position and industry contributions.
Amneal Pharmaceuticals (Nasdaq: AMRX) announced that its Co-CEO, Chirag Patel, and CFO, Tasos Konidaris, will participate in the 2024 Jefferies Healthcare Conference on June 5, 2024. Chirag Patel is scheduled to present at 1:30 PM EST. A live webcast of the presentation will be available on the company's website, with a replay accessible after the event.
Amneal Pharmaceuticals, Inc. reported a Q1 2024 net revenue of $659 million, with a GAAP net loss of $92 million and diluted loss per share of $0.30. Adjusted EBITDA was $152 million with adjusted diluted EPS of $0.14. The company settled a nationwide opioids case and affirmed its 2024 full-year guidance.
